Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Darbepoetin Alfa (Aranesp) Market Through 2029?

The market for darbepoetin alfa (aranesp) has seen consistent growth in the past few years. The market, which is predicted to expand from $5.81 billion in 2024 to $6.06 billion in 2025, displays a compound annual growth rate (CAGR) of 4.2%. The notable growth during the historic period is due to numerous factors such as advancements in anemia treatment, increased demand for erythropoiesis-stimulating agents (ESAs), innovation in biopharmaceuticals, clinical acceptance, and enhanced patient outcomes.

The market size of darbepoetin alfa (aranesp) is set to witness significant growth in the coming years, reaching “$7.37 billion by 2029 with a compound annual growth rate (CAGR) of 5.0% . This upswing in the forecast period can be credited to various factors such as healthcare reimbursement policies, heightened consciousness and education, advancement in healthcare infrastructure, demand for renal care, and an aging populace. The major trends that will mark the forecast period comprise global market penetration, integration of digital health, individualized treatment methods, embracement of biosimilars, and long-acting formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp

What Market Forces Are Driving The Darbepoetin Alfa (Aranesp) Sector In 2025 And Beyond?

The darbepoetin alfa market’s growth is expected to be driven by the rising prevalence of chronic diseases. Chronic diseases are long-term illnesses that can worsen over time, and darbepoetin alfa is used to manage these illnesses and counter the effects of chemotherapy-induced anemia in cancer patients. For instance, the Australian Institute of Health and Welfare, an Australian Government agency, reported in June 2024 that chronic diseases had caused 171,500 deaths in 2022, accounting for 90% of all fatalities with a rate of 659 per 100,000 individuals. Although the chronic disease-related age-standardised death rate decreased to 448 per 100,000 in 2020, it subsequently rose to 459 in 2021 and 490 in 2022. Therefore, the rising frequency of chronic diseases is fuelling the expansion of the darbepoetin alfa market.

How Is The Global Darbepoetin Alfa (Aranesp) Market Categorized By Segments?

The darbepoetin alfa (aranesp) market covered in this report is segmented –

1) By Type: Epogen, Procrit, Aranesp, Other Types

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications

Subsegments:

1) By Epogen: Standard Formulations, Enhanced Formulations

2) By Procrit: Standard Formulations, Biosimilars

3) By Aranesp: Single-Dose Vials, Multi-Dose Vials

4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents

How Are Key Trends Driving Expansion In The Darbepoetin Alfa (Aranesp) Industry?

In the darbepoetin alfa market, one of the emerging trends is product innovation. Key players in the market are leveraging new technologies to maintain their market position. For example, in February 2023, the UK-based pharmaceutics and biotechnology firm, GlaxoSmithKline. Ltd., gained US Food and Drug Administration (FDA) approval for their innovation, Jesduvroq (daprodustat). This medication, which is a type of recombinant human erythropoietin (rhEPO, darbepoetin alfa or epoetin alfa), serves as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. It’s utilized as a daily treatment for anemia in individuals suffering from chronic kidney disease (CKD) who have been undergoing dialysis for a period of at least four months.

Which Firms Are Considered Leaders In The Darbepoetin Alfa (Aranesp) Market Space?

Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report

What Role Do Regional Policies And Investments Play In Darbepoetin Alfa (Aranesp) Market Expansion?

North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12171&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model